Related Experiment Video

Updated: Jun 3, 2026

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

Inhibitors of MDM2 and MDMX: a structural perspective

Christiane Riedinger1, James M McDonnell

  • 1Laboratory of Molecular Biophysics, Department of Biochemistry, University of Oxford, South Parks Road, Oxford, OX1 3QU, UK. christiane.riedinger@bioch.ox.ac.uk

Future Medicinal Chemistry
|March 24, 2011
PubMed

Insights

Inhibiting MDM2 and MDMX, which counteract the tumor suppressor p53, offers a promising cancer treatment strategy. Structural insights guide the development of small molecule inhibitors targeting these interactions.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • p53 is a critical tumor suppressor frequently inactivated in cancer.
  • MDM2 and MDMX are key antagonists that inhibit p53 function.
  • Targeting the MDM2-p53 interaction is a validated therapeutic strategy.

Purpose of the Study:

  • To review the structural basis for inhibiting MDM2-p53 and MDMX-p53 interactions.
  • To summarize the functional biochemistry of p53, MDM2, and MDMX.
  • To examine recent advancements in developing inhibitors for MDM2 and MDMX.

Main Methods:

  • Analysis of structural data for MDM2-p53 and MDMX-p53 complexes.
  • Review of functional biochemistry studies.
  • Survey of recent literature on small molecule inhibitor development.

Main Results:

  • Structural knowledge of the MDM2-p53 interface has facilitated inhibitor design.
  • Emerging structural data for MDMX-p53 interactions are advancing inhibitor development.
  • Dual inhibition of MDM2 and MDMX presents a complementary therapeutic approach.

Conclusions:

  • Targeting MDM2 and MDMX is crucial for restoring p53 tumor suppressor activity.
  • Structural biology plays a vital role in developing novel cancer therapeutics.
  • Further development of MDM2 and MDMX inhibitors holds significant therapeutic potential for cancer treatment.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Combining Mitotic Cell Synchronization and High Resolution Confocal Microscopy to Study the Role of Multifunctional Cell Cycle Proteins During Mitosis08:33

Combining Mitotic Cell Synchronization and High Resolution Confocal Microscopy to Study the Role of Multifunctional Cell Cycle Proteins During Mitosis

Published on: December 5, 2017

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...